CL2008002371A1 - Composicion que comprende un polimero de hebra simple con un motivo arn inmunoestimulante; metodo que comprende poner en contacto una celula inmune capaz de producir interferon alfa con dicho polimero; y metodos para tratar el asma, una condicion alergica, el cancer y una enfermedad infecciosa. - Google Patents

Composicion que comprende un polimero de hebra simple con un motivo arn inmunoestimulante; metodo que comprende poner en contacto una celula inmune capaz de producir interferon alfa con dicho polimero; y metodos para tratar el asma, una condicion alergica, el cancer y una enfermedad infecciosa.

Info

Publication number
CL2008002371A1
CL2008002371A1 CL2008002371A CL2008002371A CL2008002371A1 CL 2008002371 A1 CL2008002371 A1 CL 2008002371A1 CL 2008002371 A CL2008002371 A CL 2008002371A CL 2008002371 A CL2008002371 A CL 2008002371A CL 2008002371 A1 CL2008002371 A1 CL 2008002371A1
Authority
CL
Chile
Prior art keywords
polymer
cancer
contacting
composition
methods
Prior art date
Application number
CL2008002371A
Other languages
English (en)
Spanish (es)
Inventor
Jurk Mario
Heinz Vollmer Jorg
Original Assignee
Coley Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002371(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coley Pharm Gmbh filed Critical Coley Pharm Gmbh
Publication of CL2008002371A1 publication Critical patent/CL2008002371A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
CL2008002371A 2007-08-13 2008-08-12 Composicion que comprende un polimero de hebra simple con un motivo arn inmunoestimulante; metodo que comprende poner en contacto una celula inmune capaz de producir interferon alfa con dicho polimero; y metodos para tratar el asma, una condicion alergica, el cancer y una enfermedad infecciosa. CL2008002371A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96444807P 2007-08-13 2007-08-13

Publications (1)

Publication Number Publication Date
CL2008002371A1 true CL2008002371A1 (es) 2009-07-03

Family

ID=40351228

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002371A CL2008002371A1 (es) 2007-08-13 2008-08-12 Composicion que comprende un polimero de hebra simple con un motivo arn inmunoestimulante; metodo que comprende poner en contacto una celula inmune capaz de producir interferon alfa con dicho polimero; y metodos para tratar el asma, una condicion alergica, el cancer y una enfermedad infecciosa.

Country Status (22)

Country Link
US (3) US8128944B2 (enExample)
EP (1) EP2179039B1 (enExample)
JP (1) JP4847609B2 (enExample)
KR (1) KR20100045508A (enExample)
CN (1) CN101821392B (enExample)
AR (1) AR067928A1 (enExample)
AU (1) AU2008288241B2 (enExample)
BR (1) BRPI0814260B8 (enExample)
CA (1) CA2696630C (enExample)
CL (1) CL2008002371A1 (enExample)
CO (1) CO6260153A2 (enExample)
DK (1) DK2179039T3 (enExample)
ES (1) ES2703876T3 (enExample)
MX (1) MX2010001014A (enExample)
NZ (1) NZ582972A (enExample)
PL (1) PL2179039T3 (enExample)
PT (1) PT2179039T (enExample)
RU (1) RU2435851C2 (enExample)
SI (1) SI2179039T1 (enExample)
TR (1) TR201820474T4 (enExample)
TW (1) TW200916106A (enExample)
WO (1) WO2009022216A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4847609B2 (ja) 2007-08-13 2011-12-28 コーリー ファーマシューティカル ゲーエムベーハー 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ
JP2010536907A (ja) * 2007-08-31 2010-12-02 ニューリミューン セラピューティクス エイジー 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
WO2013012875A2 (en) 2011-07-18 2013-01-24 Mount Sinai School Of Medicine Bacterial rnas as vaccine adjuvants
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3220895B1 (en) 2014-11-21 2022-08-31 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
MX2020006243A (es) 2017-12-15 2020-09-03 Bayer Animal Health Gmbh Oligonucleotidos inmunoestimulantes.
WO2024030844A1 (en) * 2022-08-01 2024-02-08 University Of Mississippi Choline carboxylic acid based ionic liquids as antimicrobial agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
IL112920A (en) * 1994-03-07 2003-04-10 Dow Chemical Co Composition comprising a dendritic polymer complexed with at least one unit of biological response modifier and a process for the preparation thereof
ID29546A (id) * 1999-02-15 2001-09-06 Nippon Shinyaku Co Ltd Polinukleotida dengan rantai yang diperpendek dan metode pembuatannya
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
RU2289410C2 (ru) * 2001-04-04 2006-12-20 Корикса Корпорейшн Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах
RU2185818C1 (ru) * 2001-07-10 2002-07-27 НИИ "Молекулярной медицины" Московской медицинской академии им. И.М. Сеченова Композиция для лечения легочных инфекций
IL160157A0 (en) * 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
EP1499187B1 (en) * 2002-04-04 2015-06-17 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
CN1302948C (zh) 2002-04-12 2007-03-07 爱信艾达株式会社 车载装置用电源管理系统
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US7956043B2 (en) * 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
AU2004259204B2 (en) * 2003-07-15 2010-08-19 Idera Pharmaceuticals, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
CA2555390C (en) * 2004-02-19 2014-08-05 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US8076068B2 (en) * 2005-09-14 2011-12-13 Gunther Hartmann Method for determining immunostimulatory activity of RNA oligonucleotides
ES2536103T3 (es) * 2005-11-25 2015-05-20 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimuladores
JP4847609B2 (ja) * 2007-08-13 2011-12-28 コーリー ファーマシューティカル ゲーエムベーハー 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ

Also Published As

Publication number Publication date
JP2010536739A (ja) 2010-12-02
MX2010001014A (es) 2010-03-01
BRPI0814260B8 (pt) 2021-05-25
PL2179039T3 (pl) 2019-03-29
DK2179039T3 (en) 2019-01-07
WO2009022216A3 (en) 2009-06-04
BRPI0814260A2 (pt) 2015-03-31
EP2179039A2 (en) 2010-04-28
US8227447B2 (en) 2012-07-24
CN101821392A (zh) 2010-09-01
RU2435851C2 (ru) 2011-12-10
CO6260153A2 (es) 2011-03-22
HK1143741A1 (en) 2011-01-14
CA2696630C (en) 2014-04-01
RU2010104618A (ru) 2011-09-20
AR067928A1 (es) 2009-10-28
WO2009022216A9 (en) 2009-04-30
CN101821392B (zh) 2013-04-17
CA2696630A1 (en) 2009-02-19
US20120258140A1 (en) 2012-10-11
PT2179039T (pt) 2019-01-11
WO2009022216A2 (en) 2009-02-19
US20100272785A1 (en) 2010-10-28
TR201820474T4 (tr) 2019-01-21
SI2179039T1 (sl) 2019-01-31
AU2008288241A1 (en) 2009-02-19
US8128944B2 (en) 2012-03-06
US20120121648A1 (en) 2012-05-17
NZ582972A (en) 2011-09-30
TW200916106A (en) 2009-04-16
BRPI0814260B1 (pt) 2019-11-12
US8466124B2 (en) 2013-06-18
KR20100045508A (ko) 2010-05-03
ES2703876T3 (es) 2019-03-12
AU2008288241B2 (en) 2011-12-01
JP4847609B2 (ja) 2011-12-28
EP2179039B1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
CL2008002371A1 (es) Composicion que comprende un polimero de hebra simple con un motivo arn inmunoestimulante; metodo que comprende poner en contacto una celula inmune capaz de producir interferon alfa con dicho polimero; y metodos para tratar el asma, una condicion alergica, el cancer y una enfermedad infecciosa.
MEP44608A (en) Methods for treating infectious disease exacerbated asthma
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
ATE469971T1 (de) Mikroorganismen als träger von für antigene und proteintoxine codierende nukleotidsequenzen, verfahren zur herstellung und verwendungen davon
BR112012012008A2 (pt) célula, ácidos nucleicos, enzimas e seu uso bem como processo para a produção de soforolipídios.
NZ598791A (en) Anti-gcc antibody molecules and related compositions and methods
BRPI0924622A2 (pt) composições para tratamento de tecidos, processo de fabricação, e método de uso.
CL2011003077A1 (es) Composición nutricional para mejorar el rendimiento cognitivo en un niño de 1 a 3 años, que comprende una o más fuentes de proteína, de carbohidratos disponibles, de lípidos, microorganismos probióticos, y prebióticos, en donde la una o más fuentes de lípidos comprende ácido docosahexaenoico (dha); métodos que comprenden dicha comp.
MX339878B (es) Nuevas formas solidas de clorhidrato de bendamustina.
JP2012508366A5 (enExample)
AR084377A1 (es) Metodos y composiciones relacionados con enzimas de alcohol graso biosintetico
EA201690405A1 (ru) Аэрированные композиционные материалы, способы их получения и применения
MY165006A (en) Method and compositions for producing fatty alcohols
MX2012009180A (es) Variantes y composiciones que comprenden variantes con alta estabilidad en presencia de un agente quelante.
CU20150156A7 (es) Un método para convertir una materia prima de biomasa en un producto de un ácido amino-alfa omega- dicarboxílico
EP2300938A4 (en) METHOD FOR THE REPRESENTATION OF OBJECTS AND RELATIONSHIPS IN DATABASES, DIRECT AND APPLICATIONS AS SETS
CL2009000879A1 (es) Metodo para fabricar un producto en un biorreactor que comprende cultivar microorganismos que son adaptados o mutagenizados para que exhiban por lo menos un 150% de tolerancia al producto; sistema para fabricar un producto; biorreactor.
WO2012062810A3 (en) Cell culture medium and process for protein expression, said medium and process comprising a pam inhibitor
AR053395A1 (es) Procedimiento novedoso para la reduccion enzimatica de acrilamida en productos alimenticios
AR081151A1 (es) Metodo para producir bacterias pertenecientes al genero bifidobacterium
BRPI0710405B8 (pt) comprimido de racecadotril, processo de preparação de um comprimido de racecadotril e uso de racecadotril
DK2287230T3 (da) Docetaxel polymer derivative, method for producing same and use of same
PA8813901A1 (es) Paramixovirus oncolíticos atenuados que codifican citoquinas de aves
BRPI1009574A2 (pt) Método para reduzir a produção de co2 em um processo de fermentação para produzir um álcool, e, microorganismo modificado.
CL2008003262A1 (es) Vacuna que comprende lactococcus garviae, pasteurella piscicida, vibrio anguillarum y nocardia seriolae; y uso de dichas bacterias para combatir infecciones de nocardia en peces.